Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

2017 Human Microbiome Applications in IVD and Other Healthcare Areas

This image opens in the lightbox

News provided by

Research and Markets

19 Jan, 2018, 14:00 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Jan, 19, 2018 /PRNewswire/ --

The "Human Microbiome Applications in IVD and Other Healthcare" report has been added to ResearchAndMarkets.com's offering.

Human Microbiome Applications in IVD and Other Healthcare surveys the growing interest in the human microbiome in in vitro diagnostics (IVD) and other healthcare applications, touching on areas such as metagenomics, metabolomic profiling, and microbiome diagnostics, among others.

While study of the microbiome has attracted enthusiastic media attention and venture capital, its findings are largely preliminary. Still, some IVD companies have already launched tests to measure changes in the microbiome to monitor disease progress.

Human Microbiome Applications in IVD and Other Healthcare

notes selected molecular microbiome-based tests, microbiome-based diagnostic biomarkers, and precision or personalized medicine approaches to the microbiome.

Human Microbiome Applications in IVD and Other Healthcare notes pharmaceutical company interest in the microbiome as well. Spurred on by the Human Microbiome Project, pharmaceutical companies have become more interested in microbiome research. Many players in the microbiome market are amassing knowledge and data about the microbiome in order to partner with pharmaceutical firms interested in developing new therapeutics.

Microbiome-based therapeutic approaches are discussed, including fecal microbiota transplants (FMT) and selected novel therapies. Select current microbiome-related drug candidates are noted in Human Microbiome Applications in IVD and Other Healthcare as well.

Microbiome companies and start-ups offer a wide array of products and services. They can be roughly grouped into therapeutics-based companies, research-based companies, and direct-to-consumer service providers. Despite the fact that efforts to develop microbiome-based diagnostics and therapies remain in their early stages, microbiome companies have attracted significant investment, which is discussed in the report.

Key Topics Covered:

1: Executive Summary

  • Introduction
  • Large-Scale Microbiome Projects
  • Scope Of The Report
  • Methodology

2: Human Microbiome In Ivd And Other Healthcare Applications

  • Microbiome - Bacteria In Disease Processes
  • Growing Interest In The Microbiome
  • Metagenomics
  • Metabolomic Profiling
  • Microbiome Diagnostics
  • Selected Molecular Microbiome-based Tests
  • Diagnostic Biomarkers
  • Precision or Personalized Medicine Approaches
  • PHARMA COMPANY INTEREST IN THE MICROBIOME
  • Agreements, Investments
  • Fecal Microbiota Transplantation (FMT)
  • Other Selected Microbiome-related Therapeutic Approaches
  • Microbiome Modulators
  • INVESTMENT IN MICROBIOME COMPANIES

3: Selected Microbiome Players

  • 4D Pharma plc
  • Abbott Diagnostics
  • Abbvie
  • Aces Health
  • AdvancingBio
  • Agilent Technologies Inc.
  • Anaeropharma Science
  • AOBiome, LLC
  • Aperiomics, Inc.
  • Arivale
  • Atlas Biomed
  • AvidBiotics
  • Beckman Coulter / Danaher
  • Becton, Dickinson and Company (BD)
  • Biocartis Group
  • The BioCollective
  • BioGaia Pharma AB
  • Biohit OYJ
  • Biomecite Diagnostics
  • bioMrieux Inc.
  • Bio-Rad Laboratories, Inc.
  • Biose
  • Blis Technologies
  • Bruker Corporation
  • C3J Therapeutics (formerly C3 Jian)
  • Capsugel
  • Charles River Laboratories, Inc.
  • CIPAC Therapeutics
  • CLC bio (a QIAGEN company)
  • Clinical-Microbiomics
  • Copan Diagnostics, Inc.
  • CosmosID
  • Covaris
  • Crestovo (Finch Therapeutics Group)
  • Danaher Corporation
  • Dermala
  • DermTech
  • Diversigen
  • DNA Genotek
  • DNAnexus, Inc.
  • Eagle Genomics
  • Eligo Bioscience
  • ENTEROME Bioscience SA
  • EpiBiome
  • Eppendorf AG
  • Evelo Biosciences
  • Evolve Biosystems
  • Finch Therapeutics Group
  • GALT
  • GATC Biotech AG
  • Genetic Analysis AS
  • GENEWIZ, Inc.
  • GlaxoSmithKline plc
  • Human Longevity, Inc. (HLI)
  • Illumina
  • IS-Diagnostics
  • ISOThrive LLC
  • Janssen Biotech (Johnson & Johnson)
  • Kallyope
  • Labcyte
  • Luminex Corporation
  • Mayo Medical Laboratories
  • Menarini-Silicon Biosystems
  • Merck & Co., Inc.
  • Metabiomics Corporation
  • MetaboGen AB
  • Metabolon, Inc.
  • Microbiome
  • Microbiome Insights
  • MicroBiome Therapeutics (MBT)
  • Mitra Biotech
  • MyBiotics
  • Naked Biome
  • Nestl Health Science
  • New England Biolabs
  • Nizo
  • Norgen Biotek
  • OncoImmunity
  • One Codex
  • OpenBiome
  • Optibiotix
  • OraSure Technologies, Inc.
  • Osel, Inc.
  • PerkinElmer, Inc. (Pe)
  • Pfizer, Inc.
  • Phase Genomics
  • Proderm IQ
  • Prodigest
  • Promega Corporation
  • PureFlora Inc.
  • QIAGEN
  • Quay Pharma
  • Rebiotix
  • Resphera Biosciences
  • Ritter Pharmaceuticals, Inc.
  • Roche Diagnostics
  • Sabinsa Corporation
  • ScreenCell
  • Second Genome
  • Seres Therapeutics
  • Shimadzu Corporation
  • Siolta Therapeutics
  • Symbiotic Health
  • SynCo Bio Partners B.V.
  • Synlogic
  • Synthetic Biologics
  • Thermo Fisher Scientific, Inc.
  • TNO
  • Triskelion
  • uBiome
  • Vaiomer
  • Vedanta Biosciences
  • VIOME
  • ViThera Pharmaceuticals
  • Waters Corporation
  • Whole Biome
  • Xycrobe Therapeutics, Inc.
  • Zymo Research

For more information about this report visit https://www.researchandmarkets.com/research/3v6f3p/2017_human?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.